Diabetes, Wheelchair Firms Brace For DME Impact As Rx Bill Goes To Floor
This article was originally published in The Gray Sheet
Executive Summary
Eleventh-hour efforts by Rep. David Hobson (R-Ohio) to craft language mitigating a reduction in payments for five DME product services appear to have fallen short, as the House and Senate prepare to begin floor debate on the Medicare bill
You may also be interested in...
Medicaid Insulin Pump Trial Periods Limit Patient Access, Study Says
Future studies by the Center for Insulin-Dependent Diabetes Access will assess the impact of Medicaid-mandated insulin pump trial periods in Texas and California
Medicaid Insulin Pump Trial Periods Limit Patient Access, Study Says
Future studies by the Center for Insulin-Dependent Diabetes Access will assess the impact of Medicaid-mandated insulin pump trial periods in Texas and California
Medicare Technical Corrections Legislation Doubtful After Rx Bill Passage
The resolve of House Republican leaders to avoid re-opening the controversial Medicare law with a technical corrections bill in 2004 will limit DME competitive bidding opponents' options in repealing the provision